A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix.

Trial Profile

A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Sivifene (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Therapeutic Use
  • Sponsors Kirax Corporation
  • Most Recent Events

    • 27 May 2009 Actual patient number (11) added as reported by ClinicalTrials.gov.
    • 27 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2008 The expected completion date for this trial is now 1 Aug 2008, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top